SCHEMBL4815260

SCHEMBL4815260

COCCOCC#Cc1cc(-c2n[nH]c3c2Cc2cc(Cn4cncn4)ccc2-3)cs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 1.00
KCNH2 Q12809 11/20 0.92
CSF1R P07333 4/20 0.92
FLT4 P35916 4/20 0.92
KIT P10721 3/20 0.92
LCK P06239 3/20 0.92
PDGFRB P09619 2/20 0.92
PDGFRA P16234 2/20 0.92
TEK Q02763 2/20 0.92
FLT1 P17948 3/20 0.61
FYN P06241 2/20 0.61
FLT3 P36888 2/20 0.61
MAP4K4 O95819 2/20 0.61
LYN P07948 2/20 0.61
FGFR1 P11362 2/20 0.61
CLK2 P49760 2/20 0.61
BLK P51451 2/20 0.61
CAMK2B Q13554 2/20 0.61
CAMK2G Q13555 2/20 0.61
CAMK2D Q13557 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17004664 0.96 KDR (1.00) KDRKCNH2CSF1RFLT4KIT
SCHEMBL4812046 0.90 KDR (0.89) KDRKCNH2CSF1RFLT4KIT
SCHEMBL4815812 0.90 KDR (0.82) KDRKCNH2CSF1RFLT4KIT
SCHEMBL4820265 0.89 KDR (0.87) KDRKCNH2CSF1RFLT4KIT
SCHEMBL17004663 0.89 KDR (0.87) KDRKCNH2CSF1RFLT4KIT
SCHEMBL17004674 0.88 KDR (0.78) KDRKCNH2CSF1RFLT4KIT
SCHEMBL4815906 0.87 KDR (0.77) KDRKCNH2CSF1RFLT4KIT
SCHEMBL4818932 0.87 KDR (1.00) KDRKCNH2CSF1RFLT4KIT
SCHEMBL4819585 0.86 KDR (0.90) KDRKCNH2CSF1RFLT4KIT
SCHEMBL4818668 0.85 KDR (0.86) KDRKCNH2CSF1RFLT4KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740579-B1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBVIE INC (US) 2015-08-19 EP claimed
US-7468371-B2 Tricyclic pyrazole kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-12-23 US claimed
EP-1740579-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS Abbott Laboratories (US) 2007-01-10 EP claimed
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors ABBVIE INC. 2006-01-19 US claimed
WO-2005095387-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-10-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors PRKDC, PRKACA, PIK3C3 KDR 666/4885KCNH2 2628/4885CSF1R 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.